New drug combo shows promise for tough breast cancer
NCT ID NCT03393845
First seen Jan 05, 2026 · Last updated May 09, 2026 · Updated 14 times
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to the hormone therapy fulvestrant can help control advanced breast cancer that is hormone receptor-positive and HER2-negative. About 47 adults with this type of breast cancer that has spread or cannot be removed by surgery are taking part. The goal is to see if the combination shrinks tumors or keeps the cancer stable for at least four months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Michigan State University, Breslin Cancer Center
Lansing, Michigan, 48910, United States
-
New York University Clinical Cancer Center
New York, New York, 10016, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
-
University of Wisconsin
Madison, Wisconsin, 53705, United States
Conditions
Explore the condition pages connected to this study.